# BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

> **NCT05869240** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 388 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** BPB-101

## Key facts

- **NCT ID:** NCT05869240
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-16
- **Primary completion:** 2025-08-02
- **Final completion:** 2025-09-01
- **Target enrollment:** 388 (ESTIMATED)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869240, "BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05869240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*